Navigation Links
Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference
Date:1/15/2014

n patients with diabetes in the outpatient setting. Echo is also developing its needle-free skin preparation component of Symphony, the Prelude® SkinPrep System, as a platform technology to enhance delivery of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts, including the statement about the corporate presentation, may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's ongoing studies, including the safety and efficacy of Echo's Symphony CGM System, the failure of future development and preliminary marketing efforts related to Echo's Symphony CGM System, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell the Symphony CGM System, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony CGM System. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2012, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.

For More Information:
Christine H
'/>"/>

SOURCE Echo Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Ohio , July 24, 2014  As part of ... Cardinal Health will host its annual Pharmacy Ownership Boot Camp ... Business Conference in Washington, D.C. ... the business knowledge and confidence needed to own their own ... has become the industry,s leading event for women pharmacists who ...
(Date:7/24/2014)... , July 24, 2014 Lpath, ... leader in bioactive lipid-targeted therapeutics, reported interim results ... ASONEP™ is being investigated as a treatment for ... have failed at least one therapy involving a ... more than one mTOR inhibitor (e.g., Afinitor®/everolimus), with ...
(Date:7/24/2014)... -- , Revenues from continuing operations of $1.9 ... EPS from continuing operations of $1.08, up 1.9% versus  prior ... $0.92, 7% below prior year , Cash from operations ... Full year 2014 revenues now expected to be up 2.5% ... Full year 2014 adjusted diluted EPS range narrowed to  $4.00 ...
Breaking Medicine Technology:'Women in Pharmacy' Program Seeks to Expand Pharmacy Ownership 2'Women in Pharmacy' Program Seeks to Expand Pharmacy Ownership 3'Women in Pharmacy' Program Seeks to Expand Pharmacy Ownership 4Lpath Reports Interim Data From Phase 2a Study for Anti-Cancer Drug, ASONEP 2Lpath Reports Interim Data From Phase 2a Study for Anti-Cancer Drug, ASONEP 3Lpath Reports Interim Data From Phase 2a Study for Anti-Cancer Drug, ASONEP 4Quest Diagnostics Reports Second Quarter 2014 Financial Results 2Quest Diagnostics Reports Second Quarter 2014 Financial Results 3Quest Diagnostics Reports Second Quarter 2014 Financial Results 4Quest Diagnostics Reports Second Quarter 2014 Financial Results 5Quest Diagnostics Reports Second Quarter 2014 Financial Results 6Quest Diagnostics Reports Second Quarter 2014 Financial Results 7Quest Diagnostics Reports Second Quarter 2014 Financial Results 8Quest Diagnostics Reports Second Quarter 2014 Financial Results 9Quest Diagnostics Reports Second Quarter 2014 Financial Results 10Quest Diagnostics Reports Second Quarter 2014 Financial Results 11Quest Diagnostics Reports Second Quarter 2014 Financial Results 12Quest Diagnostics Reports Second Quarter 2014 Financial Results 13Quest Diagnostics Reports Second Quarter 2014 Financial Results 14Quest Diagnostics Reports Second Quarter 2014 Financial Results 15Quest Diagnostics Reports Second Quarter 2014 Financial Results 16Quest Diagnostics Reports Second Quarter 2014 Financial Results 17Quest Diagnostics Reports Second Quarter 2014 Financial Results 18Quest Diagnostics Reports Second Quarter 2014 Financial Results 19Quest Diagnostics Reports Second Quarter 2014 Financial Results 20Quest Diagnostics Reports Second Quarter 2014 Financial Results 21Quest Diagnostics Reports Second Quarter 2014 Financial Results 22
... Calif., May 17, 2011 Asante Solutions, Inc. (Asante), ... that the U.S. Food and Drug Administration has granted ... month, the Pearl also received the CE Mark, a ... EU safety, health and environmental requirements. "We ...
... May 17, 2011 The American Association of ... Turnitin for Admissions®, Turnitin®, and iThenticate®, the global ... Turnitin for Admissions service has been selected as ... that use AACP,s Pharmacy College Application Service (PharmCAS) ...
Cached Medicine Technology:Asante Solutions Receives FDA Clearance for Pearl™ Insulin Pump 2Pharmacy College Applications Screened Using Turnitin for Admissions 2
(Date:7/24/2014)... The report, “Feed Palatability Enhancers & ... (Swine, Poultry, Cattle, Pets, Aquaculture, and Others) - Global ... feed palatability enhancers & modifiers market with an analysis ... value, of types of feed flavors, sweeteners, and text ... figures spread through 275 pages and in-depth TOC on ...
(Date:7/24/2014)... Cuyahoga County high school students are smoking tobacco products ... according to new data from the Prevention Research Center ... In 2013, more than 22 percent, or one in ... product within the prior 30 days. , Equally surprising ... and hookahs, or water pipes, more than cigarettes ...
(Date:7/24/2014)... HealthDay Reporter THURSDAY, July 24, ... funded insurance program for the poor, visit the emergency room ... insured youngsters, a U.S. survey finds. And kids with ... visit for a reason other than a serious medical problem, ... for Disease Control and Prevention. Reliance on ...
(Date:7/24/2014)... - Aristotle said, "Love is composed of a single ... that you and your partner were made in heaven ... new study. , Psychologists observe that people talk ... underlying such diversity are some common themes that frame ... frame considers love as perfect unity ("made for each ...
(Date:7/24/2014)... 2014 The South American air and missile ... 2014 and is expected to register a CAGR of 9.64% ... on tackling internal security issues like drug trafficking. Brazil is ... in the air and missile defense radar market. This is ... in the market for radar systems in terms of costal ...
Breaking Medicine News(10 mins):Health News:Feed Palatability Enhancers & Modifiers Market Worth $3172.6 Million by 2019 - Report by MarketsandMarkets 2Health News:Feed Palatability Enhancers & Modifiers Market Worth $3172.6 Million by 2019 - Report by MarketsandMarkets 3Health News:Feed Palatability Enhancers & Modifiers Market Worth $3172.6 Million by 2019 - Report by MarketsandMarkets 4Health News:Cuyahoga County high school students smoking at the same rate as adults 2Health News:Cuyahoga County high school students smoking at the same rate as adults 3Health News:Cuyahoga County high school students smoking at the same rate as adults 4Health News:Many Kids With Medicaid Use ER as Doctor's Office: CDC 2Health News:Many Kids With Medicaid Use ER as Doctor's Office: CDC 3Health News:New research: When it hurts to think we were made for each other 2Health News:South America Air and Missile Defense Radar Market is Expected to Reach $340 Million in 2020 - New Report by MicroMarket Monitor 2Health News:South America Air and Missile Defense Radar Market is Expected to Reach $340 Million in 2020 - New Report by MicroMarket Monitor 3Health News:South America Air and Missile Defense Radar Market is Expected to Reach $340 Million in 2020 - New Report by MicroMarket Monitor 4Health News:South America Air and Missile Defense Radar Market is Expected to Reach $340 Million in 2020 - New Report by MicroMarket Monitor 5
... (FHC) has received an initial order for the supply ... AIDS Control Organisation (NACO). ,"The condoms will be ... and distribution will initially be focused on commercial sex ... Pradesh, Karnataka, Maharastra) in India," said a statement issued ...
... A new study has pointed out the alarming incidence of ... more than 25 million people, approximating// to one-fifth of the ... stroke. ,In view of this health threat, the ... in the diet and do more exercise, if these effects ...
... officials, investigating the incidence of fungal infection in Bausch and ... the infection. The only association arrived at is that nearly ... used a lens cleansing solution, manufactured by Bausch and Lomb. ... contact lens and lens solution, feels that the cause of ...
... have revealed that cooked tomatoes contain an ingredient called ... cardiovascular disease// . ,Lycopene, is a bright ... other red fruits. Lycopene is the most common carotenoid ... most potent carotenoid antioxidants. ,Besides tomatoes other ...
... nation’s first test tube babies, both girls, as a testament ... as Agnes and as Jane are overjoyed and are in ... 300,000 Kenyan shillings (?2,275) for the now rather commonplace in ... Louise Brown was born in Oldham, U.K on July 25, ...
... had warned that office workers sit at their computer screens ... of being affected by deep vein thrombosis. ,This ... Bristol almost died after a 12-hour stint in front of ... the first cases in the UK of a growing phenomenon ...
Cached Medicine News:Health News:US Firm To Supply Female Condoms To India 2Health News:Testtube Babies Born in Kenya 2
Inquire...
The new Gemini EM microplate spectrofluorometer builds on the successful Gemini platform. This next generation reader incorporates all of the high performance features of the Gemini XS with new capab...
The Fluoroskan Ascent FL is equipped with both fluorometric and luminometric measurement technologies, providing a full coverage for fluorometric, glow and flash luminometric applications even in the...
... from Berthold Technologies, has been designed ... measurement modes to support academic and ... ratio measurements plus top and bottom ... for any researcher using fluorescence in ...
Medicine Products: